Pathophysiology and therapeutic options for cirrhotic portal hypertension.

Guixé-Muntet, Sergi; Quesada-Vázquez, Sergio; Gracia-Sancho, Jordi (2024). Pathophysiology and therapeutic options for cirrhotic portal hypertension. The lancet. Gastroenterology & hepatology, 9(7), pp. 646-663. Elsevier 10.1016/S2468-1253(23)00438-7

Text 1-s2.0-S2468125323004387-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Portal hypertension represents the primary non-neoplastic complication of liver cirrhosis and has life-threatening consequences, such as oesophageal variceal bleeding, ascites, and hepatic encephalopathy. Portal hypertension occurs due to increased resistance of the cirrhotic liver vasculature to portal blood flow and is further aggravated by the hyperdynamic circulatory syndrome. Existing knowledge indicates that the profibrogenic phenotype acquired by sinusoidal cells is the initial factor leading to increased hepatic vascular tone and fibrosis, which cause increased vascular resistance and portal hypertension. Data also suggest that the phenotype of hepatic cells could be further impaired due to the altered mechanical properties of the cirrhotic liver itself, creating a deleterious cycle that worsens portal hypertension in the advanced stages of liver disease. In this Review, we discuss recent discoveries in the pathophysiology and treatment of cirrhotic portal hypertension, a condition with few pharmacological treatment options.

Interest & Impact

Downloads

0 since deposited on 25 Apr 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item